In a clinical study, the same group observed that BBR significantly lowered fasting blood glucose (FBG), hemoglobin A1c, triglycerides, and insulin levels in patients with T2DM as well as metformin and rosiglitazone (a combination commonly used for the T2DM therapy); the percentages of peripheral blood lymphocytes expressing InsR were significantly elevated after therapy [81]. This evidence concerns the gene INS and type 2 diabetes mellitus.